/NGEN.V
NGEN.V Stock - NervGen Pharma Corp.
Healthcare|BiotechnologyTSXV
$6.85+9.60%
+$0.60 (+9.60%) • Dec 22
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.98
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.89
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $7.54
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NGEN.V
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.78 – $6.92
TARGET (TP)$7.88
STOP LOSS$6.30
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.77
52W High$7.05
52W Low$2.57
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-83,798 | $-145,003 | $-115,114 | $-42,626 | $-39,645 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-24,931,995 | $-17,776,710 | $-22,823,637 | $-12,866,453 | $-11,186,775 |
| Net Income | $-24,005,895 | $-22,382,120 | $-18,106,330 | $-12,641,932 | $-11,176,398 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.36 | $-0.38 | $-0.34 | $-0.32 | $-0.35 |
Company Overview
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NGEN.VBeat Rate
43%
Last 14 quarters
Avg Surprise
-5.8%
EPS vs Estimate
Beats / Misses
6/6
2 met exactly
Latest EPS
$-0.06
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
+57.6%
$-0.04vs$-0.09
Q3 24
-22.2%
$-0.11vs$-0.09
Q4 24
+22.2%
$-0.07vs$-0.09
Q2 25
-62.5%
$-0.13vs$-0.08
Q2 25
+33.3%
$-0.06vs$-0.09
Q3 25
-110.9%
$-0.13vs$-0.06
Q4 25
0.0%
$-0.06vs$-0.06
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q4 2025 | Nov 25, 2025 | $-0.06 | $-0.06 | 0.0% | = MET |
Q3 2025 | Aug 27, 2025 | $-0.06 | $-0.13 | -110.9% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.09 | $-0.06 | +33.3% | ✓ BEAT |
Q2 2025 | Apr 3, 2025 | $-0.08 | $-0.13 | -62.5% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.09 | $-0.07 | +22.2% | ✓ BEAT |
Q3 2024 | Aug 22, 2024 | $-0.09 | $-0.11 | -22.2% | ✗ MISS |
Q2 2024 | Apr 23, 2024 | $-0.09 | $-0.04 | +57.6% | ✓ BEAT |
Q1 2024 | Mar 29, 2024 | — | $-0.14 | — | — |
Q4 2023 | Nov 9, 2023 | — | $-0.07 | — | — |
Q3 2023 | Aug 9, 2023 | — | $-0.08 | — | — |
Q2 2023 | Apr 28, 2023 | $-0.12 | $-0.10 | +16.7% | ✓ BEAT |
Q1 2023 | Mar 27, 2023 | $-0.12 | $-0.09 | +26.5% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.14 | $-0.08 | +42.9% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-0.11 | $-0.13 | -18.2% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.08 | $-0.11 | -37.5% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-0.09 | $-0.09 | 0.0% | = MET |
Q4 2021 | Nov 18, 2021 | $-0.07 | $-0.09 | -28.6% | ✗ MISS |
Q3 2021 | Aug 19, 2021 | — | $-0.07 | — | — |
Q2 2021 | May 20, 2021 | — | $-0.06 | — | — |
Latest News
Loading news...
Frequently Asked Questions about NGEN.V
What is NGEN.V's current stock price?
NervGen Pharma Corp. (NGEN.V) is currently trading at $6.85 per share. The stock has moved +9.60% today.
What is the analyst price target for NGEN.V?
No analyst price targets are currently available for this stock.
What sector is NervGen Pharma Corp. in?
NervGen Pharma Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the TSXV exchange.
What is NGEN.V's market cap?
NervGen Pharma Corp. has a market capitalization of $0.54 billion, making it a small-cap company.
Does NGEN.V pay dividends?
No, NervGen Pharma Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCYBN.NE
Cybin Inc.
$9.79
Mkt Cap: $0.2B
DR.TO
Medical Facilities Corporation
$15.48
Mkt Cap: $0.3B
EPRX.TO
Eupraxia Pharmaceuticals Inc.
$9.70
Mkt Cap: $0.3B
FRX.TO
Fennec Pharmaceuticals Inc.
$10.63
Mkt Cap: $0.3B
HBP.TO
Helix BioPharma Corp.
$2.29
Mkt Cap: $0.2B
HLS.TO
HLS Therapeutics Inc.
$4.75
Mkt Cap: $0.1B
MDNA.TO
Medicenna Therapeutics Corp.
$0.99
Mkt Cap: $0.1B
MSCL.TO
Satellos Bioscience Inc.
$0.66
Mkt Cap: $0.1B
PRN.TO
Profound Medical Corp.
$10.03
Mkt Cap: $0.3B
XLY.TO
Auxly Cannabis Group Inc.
$0.15
Mkt Cap: $0.2B
Explore stocks similar to NGEN.V for comparison